---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-24-000893"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:31:32.089248+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunic appoints Jason Tardio as COO/President and promotes Werner Gladdines to CDO

## Summary
- Jason Tardio, former Novartis MS franchise head and Biogen exec, appointed COO and President effective July 12, 2024.
- Tardio will lead launch preparedness for vidofludimus calcium (IMU-838) and partnership efforts.
- Compensation: $500,000 base salary, up to 40% bonus, $120,000 signing bonus, and 500,000 stock options with 4-year vest.
- Werner Gladdines promoted from VP to Chief Development Officer, overseeing clinical operations.
- Phase 2 CALLIPER trial in progressive MS readout expected April 2025; phase 3 ENSURE trials in relapsing MS due 2026.

## SEC filing metadata
- accession: 0001193805-24-000893
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380524000893/0001193805-24-000893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380524000893/e663765_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-24-000893
- JSON: https://secwatch.observer/filing/0001193805-24-000893.json
- Plain text: https://secwatch.observer/filing/0001193805-24-000893.txt

## Key facts
- Executive change
  Jason Tardio was appointed as Chief Operating Officer and President at IMMUNIC, INC..
  - Action: appointed
  - Role: Chief Operating Officer and President
  source text: appointment of Jason Tardio as Chief Operating Officer and President, effective July 12, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380524000893/0001193805-24-000893-index.htm
- Executive change
  Werner Gladdines changed role as Chief Development Officer at IMMUNIC, INC..
  - Action: promoted
  - Role: Chief Development Officer
  source text: promotion of Werner Gladdines from Vice President, Program Management & Clinical Development Operations to Chief Development Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380524000893/0001193805-24-000893-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.